Compare iShares MSCI France ETF (EWQ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Mesoblast Limited — how do they compare? iShares MSCI France ETF trades at $47.49, while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: iShares MSCI France ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| EWQ | MESO | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $48.35 | $20.96 |
52-Week Low | $41.68 | $12.88 |
Market Cap | — | $2.21B |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ (iShares MSCI France ETF) trades at $47.51, down 0.5% on the day, with a bullish technical signal driven by moving averages. The ETF offers exposure to French equities with a 15.3x P/E ratio and favorable PEG of 1.6x according to Seeking Alpha (August 4, 2026). Recent institutional activity shows Allspring Global reduced its position by 26.2% in Q1 2026, while European central bank policy remains a key market driver.
The outlook for EWQ remains positive with French stocks hitting new highs and attractive valuations supporting further upside. Key risks include ECB monetary policy uncertainty amid Middle East tensions and potential production constraints at French nuclear facilities. The concentrated industrial sector exposure (32%) provides growth potential but increases sector-specific vulnerability.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
